Charity Intelligence Canada - Charity Home Page

Juvenile Diabetes Research Foundation Canada

Sector: Health

Operating Charity

800-2550 Victoria Park Avenue
Toronto, ON M2J 5A9
President & CEO: Andrew McKee
Board Chair: Aubrey Baillie

Website: www.jdrf.ca
Charitable Reg. #: 11897 6604 RR0001

About Juvenile Diabetes Research Foundation Canada:

Founded in 1974 by parents of children with diabetes, Juvenile Diabetes Research Foundation Canada (JDRF) works to raise money to fund research to find a cure for diabetes, focusing on type 1 diabetes and its complications. JDRF reports that 300,000 Canadians live with type 1 diabetes. A diabetic who uses insulin with a needle will require approximately 1,460 needles a year to manage the disease. Type 1 diabetes often leads to life-threatening and debilitating complications which may include kidney failure, blindness, heart disease, stroke, nerve damage and amputation. JDRF has 14 chapters across Canada that provide research updates and information to people living with diabetes.

JDRF is one of six international affiliates of Juvenile Diabetes Research Foundation International, the world's largest charitable funder of diabetes science. In F2008, JDRF granted $9.8m to 47 Canadian doctors focused on type 1 diabetes research, including its contribution to international research. Research funding is diversified over 4 areas – immune therapies, beta cell therapies, glucose control, and complication therapies. JDRF highlights the increase in human clinical trials which indicate taking research from the lab to practical application, from 5 trials in 2003 to 50 trials in 2011.

Financial Review:

JDRF's administrative costs are 5% of revenues and fundraising costs are 32% of donations. JDRF has funding reserves of $7.3m (including $85,500 in donor- endowed funds) that cover 54% of annual program costs.

Financial Ratios Fiscal year ending December	2010	2009	2008
Administrative costs as % of revenues	9.6%	4.6%	4.7%
Fundraising costs as % of donations	30.9%	30.1%	32.0%
Program cost coverage (%)	35.1%	76.7%	53.7%

Summary Financial Statements All figures in $000s	2010	2009	2008
Donations	22,105	22,095	20,889
Government funding	5,691	0	0
Investment income	44	30	211
Total revenues	27,840	22,126	21,101
Program costs	11,962	3,500	3,739
Grants	8,294	8,878	9,782
Administrative costs	2,680	1,027	989
Fundraising costs	6,833	6,645	6,684
Cash flow from operations	(1,928)	2,076	(93)
Funding reserves	7,109	9,492	7,265

Note: Ci has reported fundraising revenues on a gross basis, increasing revenues and expenses by $4.5M in F2008, $4.4M in F2007, and $3.8M in F2006. As well unrealized gains on short term investments have been removed.

Comments added by the Charity:

JDRF directs funds to deliver both near-term benefits for people who live with type 1 diabetes and, ultimately, a cure. Our research focus is on two distinct and related aims of science leading to a cure and science leading to better treatments. JDRF also provides outreach support services, volunteer and advocacy opportunities.

Canada’s excellence in diabetes research and breakthroughs continues in the creation of the JDRF Canadian Clinical Trial Network. Launched in 2010 through a partnership with the Government of Canada, JDRF CCTN began as a $33.9M investment to accelerate the testing of new technologies and treatments for Canadians living with type 1 diabetes and its complications.

JDRF is positively impacting the lives and futures of people living with diabetes. Thanks to the support of our generous donors, JDRF has made significant advancements and progress toward positive health outcomes for people living with type 1 diabetes. For example:

JDRF-funded research with industry partners on immune therapies is progressing to the most advanced stages of clinical testing
JDRF now funds over 50 human clinical trials, as opposed to five in 2003.
JDRF is perfecting insulin treatments, a critical component of JDRF’s Artificial Pancreas Project and impact on the daily lives of those living with type 1 diabetes.
Recent advances in diabetic eye disease, funded in part by JDRF, hold the potential to help prevent and reverse eye disease in people with type 1 diabetes.

We remain committed to a cure while investing in better treatments for today.